|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 July 2003, Vol. 102, No. 2, pp. 772-773
CORRESPONDENCE
To the editor:
Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients
The t(4;14) translocation in multiple myeloma (MM) is identified in 15% of patient samples and dysregulates both FGFR3 and multiple myeloma SET domain (MMSET).1 Activating FGFR3 mutations are observed in cell lines and late-stage MM, but the incidence of mutation in newly diagnosed patients, although not well characterized,2 is likely pivotal in MM progression.3 We therefore selected CD138+ cells from the bone marrow of 150 newly diagnosed MM patients. cDNA from selected cells was hybridized to HuGeneFL GeneChip microarrays (Affymetrix, Santa Clara, CA).4 FGFR3 overexpression was noted in 24 patients (16%). Reverse transcriptase–polymerase chain reaction (RT-PCR) and fluorescence in situ hybridization (FISH) subsequently confirmed that all of the FGFR3-positive patients carried the t(4;14) translocation (Figure 1A). The entire open reading frame of FGFR3 was then amplified and bidirectionally sequenced in triplicate, which identified mutation in 2 patients. One patient harbored a 6-bp insertion 5'-AACAGT-3' at nucleotide position 1306, which was unique to the FGFR3 IIIb isoform, implying a splice variant (Figure 1Bi). In a second patient, a point mutation was observed at nucleotide number 761A>G resulting in a Tyr241Cys (tyrosine to cysteine change) located in the linker region between immunoglobulin-like domain I and immunoglobulin-like domain II (Figure 1Bii
[PDB]
). This genetic change is in close proximity to other previously identified activating mutations. Together these data indicate that mutation of FGFR3 is observed in less than 5% of t(4;14)-positive and in only 1 of 150 newly diagnosed MM patients overall. Incorporating findings from the literature5-9 with our larger study, 52 (15%) of 348 myeloma patients have a t(4;14) and 3 (6%) of the 52 translocation-positive patients have a potential activating mutation of FGFR3, or 3 (< 1%) of 348 overall.
View larger version (78K):
[in this window]
[in a new window]
|
Figure 1.. FGFR3 gene translocation and mutation screening in MM patients. (A) Detection of immunoglobulin heavy chain (IgH)/MMSET fusion product using translocation-specific RT-PCR5 (a lanes represent MMSET + JH PCR, whereas b lanes represent MMSET + 1 m PCR). Of 24 patient samples, 22 are positive: 5 patients have a translocation breakpoint as in the myeloma cell line KMS11, 9 patients have a breakpoint like H929, and 8 patients have an OPM2 breakpoint. (B) Genetic changes of FGFR3 gene in patient samples. (i) Sequence analysis of cloned cDNA of patient no. 1 revealed a 6-bp insertion of 5'-AACAGT-3' at nucleotide position 1306, resulting in an insertion of amino acids threonine and cysteine. (ii) Point mutation at nucleotide 761A>G resulting in tyrosine to cysteine change in FGFR3 codon 241 (patient no. 23, sequencing from reverse direction of the gene). (iii) Of 22 patient samples, 17 carry C to T transition in FGFR3 codon 294. (C) Different isoforms of FGFR3 are detected in patient nos. 15 and 16. Patient nos. 15 and 16 expressed the FGFR3 IIIc isoform (upper band) and novel isoforms devoid of Ig-like domain I and of both domain I and the acid-box, respectively, (lower band) while patient no. 18 expressed only FGFR3 IIIc isoform.
|
|
To determine the single nucleotide polymorphism (SNP) profile of FGFR3 we next examined the Celera database and identified 21 SNPs pertaining to the coding region of FGFR3. One of these SNPs, 921C>T, was identified in 17 of 22 FGFR3 sequences (Figure 1Biii). Using the SNP human database (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi) this 294C>T polymorphism has an allele frequency of 0.877. The 77% SNP incidence in the patient samples is therefore not statistically different from that of the general human population.
Our patient samples expressed different FGFR3 isoforms by sequencing, with the FGFR3 IIIc isoform being most prevalent. We also identified 2 novel FGFR3 isoforms in MM plasma cells: an isoform devoid of immunoglobulin-like domain I and an isoform that is devoid of both domain I and the acid-box (Figure 1C). Interestingly, although both isoforms have ligand-binding properties similar to those of the full-length receptor, they have previously been reported to have a higher affinity for the FGFR ligand.10
In summary, our comprehensive analysis of 150 newly diagnosed MM patients has demonstrated that overexpression of FGFR3 is seen in 16% of newly diagnosed patients, overexpression is observed only in the presence of the t(4;14), and activating mutations of FGFR3 are rare in newly diagnosed MM patients. The 294C>T polymorphism is common in MM patients and a number of different isoforms of the gene are expressed (the significance of which is uncertain).
Obiageli N. Onwuazor,
Xiao-Yan Wen,
Ding-Yan Wang,
Lihua Zhuang,
Esther Masih-Khan,
Jaimie Claudio,
Bart Barlogie,
John D. Shaughnessy, Jr, and
A. Keith Stewart
Correspondence: Keith Stewart, Department of Medical Oncology, 5th Fl Rm 126, The Princess Margaret Hospital, 610 University Ave, Toronto, Ontario M5G 2M9, Canada; e-mail: kstewart{at}uhnres.utoronto.ca
References
- Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3; q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997;16: 260-264.[CrossRef][Medline]
[Order article via Infotrieve]
- Richelda R, Ronchetti D, Baldini L, et al. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood. 1997;90: 4062-4070.[Abstract/Free Full Text]
- Plowright EE, Li Z, Bergsagel PL, et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood. 2000;95: 992-998.[Abstract/Free Full Text]
- Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99: 1745-1757.[Abstract/Free Full Text]
- Malgeri U, Baldini L, Perfetti V, et al. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res. 2000; 60: 4058-4061.[Abstract/Free Full Text]
- Fracchiolla NS, Luminari S, Baldini L, Lombardi L, Maiolo AT, Neri A. FGFR3 gene mutations associated with human skeletal disorders occur rarely in multiple myeloma. Blood. 1998;92: 2987-2989.[Free Full Text]
- Intini D, Baldini L, Fabris S, et al. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br J Haematol. 2001;114: 362-364.[CrossRef][Medline]
[Order article via Infotrieve]
- Sibley K, Fenton JA, Dring AM, Ashcroft AJ, Rawstron AC, Morgan GJ. A molecular study of the t(4;14) in multiple myeloma. Br J Haematol. 2002;118: 514-520.[CrossRef][Medline]
[Order article via Infotrieve]
- Soverini S, Terragna C, Testoni N, et al. Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis. Haematologica. 2002;87: 1036-1040.[Abstract/Free Full Text]
- Shimizu A, Takashima Y, Kurokawa-Seo M. FGFR3 isoforms have distinct functions in the regulation of growth and cell morphology. Biochem Biophys Res Commun. 2002;290: 113-120.[Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Masih-Khan, S. Trudel, C. Heise, Z. Li, J. Paterson, V. Nadeem, E. Wei, D. Roodman, J. O. Claudio, P. L. Bergsagel, et al.
MIP-1{alpha} (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma
Blood,
November 15, 2006;
108(10):
3465 - 3471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Keats, C. A. Maxwell, B. J. Taylor, M. J. Hendzel, M. Chesi, P. L. Bergsagel, L. M. Larratt, M. J. Mant, T. Reiman, A. R. Belch, et al.
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients
Blood,
May 15, 2005;
105(10):
4060 - 4069.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Dring, F. E. Davies, J. A. L. Fenton, P. L. Roddam, K. Scott, D. Gonzalez, S. Rollinson, A. C. Rawstron, K. S. Rees-Unwin, C. Li, et al.
A Global Expression-based Analysis of the Consequences of the t(4;14) Translocation in Myeloma
Clin. Cancer Res.,
September 1, 2004;
10(17):
5692 - 5701.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
